Press releaseGlobe Newswire
MBX Biosciences
MBX · NASDAQ
$53.50+$1.02 (+1.94%)TodayMarket closed ·
Prev close $52.48
Latest news
- Press releaseGlobe Newswire
MBX Biosciences to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
- Press releaseGlobe Newswire
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
- Press releaseGlobe Newswire
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
- NewsAvi Kapoor
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
- Press releaseGlobe Newswire
Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Press releaseGlobe Newswire
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
- NewsVandana Singh
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
- NewsAvi Kapoor
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Press releaseGlobe Newswire
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
- Press releaseGlobe Newswire
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
- Press releaseGlobe Newswire
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
- News
Earnings Scheduled For May 14, 2026
- Press releaseGlobe Newswire
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
- Press releaseGlobe Newswire
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
- Press releaseGlobe Newswire
MBX Biosciences to Participate in Upcoming March Investor Conferences
- News
Earnings Scheduled For February 12, 2026
- Press releaseGlobe Newswire
MBX Biosciences to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
- NewsAvi Kapoor
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
- News
Earnings Scheduled For December 18, 2025
- Press releaseGlobe Newswire
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
- Press releaseGlobe Newswire
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
- Press releaseGlobe Newswire
MBX Biosciences to Participate in November Investor Conferences
- Press releaseGlobe Newswire
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
- NewsAvi Kapoor
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
- NewsRishabh Mishra
Stock Market Today: Dow Futures Rise, Nasdaq, S&P 500 Slip Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focus (UPDATED)
- NewsAvi Kapoor
AutoZone, Micron Technology And 3 Stocks To Watch Heading Into Tuesday
- NewsAvi Kapoor
Gold Gains Over 1%; Quantum Computing Shares Plunge
- NewsAvi Kapoor
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In August
- News
Market-Moving News for September 22nd
- Press releaseGlobe Newswire
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
- Press releaseGlobe Newswire
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
- News
Earnings Scheduled For August 14, 2025
- News
A Glimpse of MBX Biosciences's Earnings Potential
- Press releaseGlobe Newswire
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
- Press releaseGlobe Newswire
MBX Biosciences to Participate in June Investor Conferences
- Press releaseGlobe Newswire
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
- Press releaseGlobe Newswire
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
- Press releaseGlobe Newswire
MBX Biosciences to Participate in March Investor Conferences
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
MBX Biosciences to Participate in Upcoming February Investor Conferences
- NewsAvi Kapoor
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.